retatrutide mechanism triple agonist gip glp-1 glucagon receptor A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology 🚨 HOT OFF THE PRESS:

Individual clones of HEK293 cells stably expressing select FRET reporters were obtained by G418 antibiotic resistance selection, as described previously 34

It produces more modest results than semaglutide or tirzepatide, typically around 8 percent body weight loss, but it was the first GLP-1 to receive FDA approval specifically for weight management and remains a viable option for patients who prefer a shorter-acting medication or who experience intolerable side effects on the more potent formulations

Meloni AR, DeYoung MB, Lowe C, et al

What makes Low-Temperature Spray Drying (LTSD) superior

Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, et al